Introduction
Transplantation of cadaveric human β-cells can restore insulin-independence in patients with type 1 diabetes (T1D (1, 2)), but is not widely available to most patients due to the inadequate supply of donor cells and burden of immunosuppression. Pluripotent stem cells are a highly scalable alternative cell source (3) and we have previously demonstrated that human stem cell-derived pancreatic progenitor cells can reverse hyperglycemia in mouse models of streptozotocin (STZ)-induced T1D (4) (5) (6) , and high fat diet-induced type 2 diabetes (7). However, glucose-responsive human insulin secretion was only achieved after a lengthy cell maturation period in vivo and it remains unclear how environmental factors within the host may impact this maturation process. Viacyte Inc. has initiated phase 1/2 clinical trials involving transplant of macroencapsulated human embyronic stem cell (hESC)-derived pancreatic progenitor cells into patients with T1D. Thus, it is important to understand how variability in the physiology of transplant recipients may impact the development of progenitor cells in vivo.
Patients with diabetes have a significantly higher risk of developing thyroid disease than the general population (8) . Up to one-third of patients with T1D also have thyroid dysfunction, which can exacerbate the impaired metabolic control and complications associated with diabetes, particularly when the thyroid disorder is undetected (8) . Moreover, there is evidence to suggest that excessive or deficient levels of thyroid hormones may impact β-cell development and function. Maternal hypothyroidism caused impaired insulin secretion in neonatal rats, as well as glucose intolerance and β-cell dysfunction in adult offspring (9) .
Systemic knockout of Dio3 (the enzyme required for intracellular inactivation of thyroid hormones), caused significantly reduced islet area and pancreatic insulin content compared to
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wild-type mice at birth, as well as glucose intolerance and impaired insulin secretion during adulthood (10). Triiodothyronine (T3) has also been shown to have pro-survival effects on adult β-cells by protecting mice from STZ-induced β-cell death and diabetes (11) . AguayoMazzucato and colleagues demonstrated that daily T3 injections from postnatal days 1-7 in rats increased expression and nuclear localization of Mafa, a transcription factor essential for β-cell maturation, whereas inhibition of postnatal thyroid hormone synthesis decreased Mafa levels in neonatal rat islets (12) . Moreover, treatment of isolated neonatal rat islets with T3 in vitro induced glucose-stimulated insulin secretion, an effect that was blocked in the presence of dominant negative-Mafa, suggesting that the effects of T3 on β-cell maturation are via Mafa regulation (12) . Consistent with these findings, addition of T3 to differentiating hESCs increased gene expression of INS and MAFA, and led to improved glucose-stimulared insulin secretion (13) . Taken together, these studies suggest that thyroid hormone signaling may play an important role in β-cell development, maturation, survival, and maintenance of adult β-cell function.
Here, we investigated the effects of thyroid hormone dysregulation on the maturation of encapsulated hESC-derived pancreatic progenitor cells in vivo. We hypothesized that hyperthyroidism may accelerate the development of hESC-derived pancreatic progenitor cells into mature insulin-secreting cells, whereas hypothyroidism may hinder the maturation process. Our findings indicate that chronic hypothyroidism impairs the development of hESCderived β-cells in vivo, and instead promotes the formation of α-and ε-cells from pancreatic progenitor cells. Short-term exposure to hyperthyroidism for 4 weeks post-transplant did not impact the development of glucose-dependent human insulin production from pancreatic progenitor cells in vivo.
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Research Design and Methods
In Vitro Differentiation of hESCs and Assessment of Pancreatic Progenitor Cells
The Pluripotent H1 cells were differentiated into pancreatic progenitor cells for transplantation studies according to a 14-day, 4-stage protocol as previously described (4) . Expression of key pancreatic progenitor cell markers was assessed prior to transplant using flow cytometry, as previously described (5); antibody information is provided in Supplementary Table 1. To determine the effect of T3 on hESC development in vitro, H1 cells were differentiated according to our recently published protocol (13) , and T3 was added during Stage 4 (S4; 500 nM or 1000 nM final concentration). Differentiated cells were assessed by qPCR on S4, day 3 (S4D3), S5D3 and S6D3, as described below.
Animals
Male 7-8 week old SCID-beige mice (C.B-Igh-1b/GbmsTac-Prkdc scid -Lyst bg N7; Taconic, Hudson, NY) were maintained on a 12h light/dark cycle throughout the study. The first cohort of mice (7-8 weeks of age) was used to characterize the different models of thyroid dysregulation: chronic hypothyroid (n=10), chronic hyperthyroid (n=10), and euthyroid (n=10); the treatment protocol is summarized in Fig. 1A and described in detail below. A subset of mice from this cohort was subsequently used for transplantation, as summarized in Fig. 2A . The chronic hypothyroid group was maintained on an iodine-deficient diet (n=8) and 
Diets and L-Thyroxine Administration
All mice received ad libitum access to a standard irradiated diet (Teklad Diet #2918; Harlan Laboratories, Madison, WI, USA) to allow for acclimatization following their arrival at UBC.
At 12-13 weeks old, mice from the first cohort were randomly selected to undergo one of the following treatments (summarized in Fig. 1A For the mice that received cell transplants, five treatment groups were followed for 180 days post-transplant (summarized in Fig. 2A ). Euthyroid mice (A and B) and the acute hyperthyroid mice received the iodine control diet for the duration of the study. The acute
Page 6 of 48 Diabetes
hyperthyroid group received T4 drinking water (3 mg/L) for 1 week before and 4 weeks following transplantation. The acute hypothyroid mice received the iodine-deficient diet with 0.15% PTU for 4 weeks following transplantation and the chronic hypothyroid mice received the iodine-deficient diet for the duration of the study.
Transplantation of hESC-Derived Pancreatic Progenitor Cells
Euthyroid (A), chronic and acute hypothyroid mice received hESC-derived pancreatic progenitor cell transplants at 20-21 weeks of age (after 8-9 weeks of treatment regimes; Fig.   2A ). Euthyroid (B) and acute hyperthyroid mice received cell transplants at 10 weeks of age ( Fig. 2A) . All mice were anaesthetized with inhalable isoflurane and ~5x10 6 hESC-derived pancreatic progenitor cells were transplanted subcutaneously (s.c.) within a 20 µl Theracyte TM macroencapsulation device (TheraCyte Inc., Laguna Hills, CA) on the right flank, as previously described (4).
Metabolic Assessments
All metabolic analyses were performed in conscious, restrained mice and blood samples were collected via saphenous vein at the indicated time points. Specific assays used to measure plasma analytes and detailed protocols for metabolic testing are described in the Supplementary Data.
Quantitative RT-PCR
Theracyte TM devices were harvested at 27 weeks post-transplant from all mice for qPCR analysis. Devices were cut longitudinally and one half was stored in RNAlater Stabilization 
Statistical Analysis
All statistics were performed using GraphPad Prism software (GraphPad Software Inc., La Jolla, CA). Details about individual statistical tests are provided in the Supplementary Data.
For all analyses, p<0.05 was considered statistically significant. Data are presented as mean ± SEM with individual data points.
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Results
Chronic hypothyroidism induced weight loss and hyperglycemia, whereas chronic hyperthyroidism induced hypoglycemia and hyperinsulinemia in SCID-beige mice Our first goal was to establish a protocol to induce hyperthyroidism or hypothyroidism in SCID-beige mice (outlined in Fig. 1A ). Initially there were no differences in plasma T3 levels between groups, but T3 levels were significantly reduced following 14 days of feeding with an iodine-deficient diet compared to an iodine control diet (euthyroid) (Fig. 1B) . In contrast, the addition of thyroxine (T4) to drinking water produced dose-dependent increases in plasma T3 levels. A dose of 12 mg/L for 7 days, followed by 6 mg/L for 7 days produced plasma T3 levels in the hyperthyroid mice that were ~10-15-fold higher than the euthyroid group (Fig. 1B) , but much higher than T3 levels reported in humans with clinical hyperthyroidism (euthyroid: 3.3 ± 0.7 ng/mL; hyperthyroid: 7.1 ± 1.0 ng/mL (15) ). Therefore, the dose of T4 was further reduced to 3 mg/L to achieve clinically relevant plasma T3 levels (Fig. 1B) and in an effort to prevent the severe hypoglycemia observed with higher T4 doses (Fig. 1D,E ).
Mice displayed an initial reduction in body weight following administration of the iodine-deficient diet, which recovered and stabilized after 12 days of treatment, but remained significantly lower than euthyroid controls (Fig. 1C) . There was no effect of hyperthyroidism on body weight (Fig. 1C) . Hypothyroidism caused significantly elevated blood glucose levels both under fasting conditions (Fig. 1D) and following an oral glucose challenge (Fig. 1E) , whereas hyperthyroidism resulted in significantly decreased blood glucose levels (Fig. 1D,E) .
Hyperthyroidism was also associated with significantly higher fasting plasma insulin levels Page 9 of 48 Diabetes compared to euthyroid controls (Fig. 1F) . Unfortunately, after 24 days of T4 treatment, four of ten hyperthyroid mice died and the remaining mice were consequently switched to normal drinking water, resulting in return to normoglycemia within 2 weeks (Fig. 1D ).
Thyroid hormone deficiency hinders the development of hESC-derived progenitor cells into mature insulin-secreting cells in vivo
We next assessed the effects of either excessive or deficient thyroid hormone levels on the development of hESC-derived pancreatic progenitor cells in vivo. Following the 14-day differentiation in vitro, hESC-derived cells were ~99.5% PDX1-positive and 70% NKX6.1-positive prior to transplant (Supplementary Fig. 1 ), consistent with previous studies (5) (6) (7) 13) .
The progenitor population also contained ~14% endocrine cells, which co-expressed NKX2.2, but were largely NKX6.1-negative ( Supplementary Fig. 1 ). These pancreatic progenitor cells were transplanted subcutaneously within Theracyte TM devices into mice with thyroid hormone dysregulation (as outlined in Fig. 2A ). Our experimental groups enabled us to examine the impact of acute exposure to deficient or excessive thryoid hormone during the first 30 days post-transplant and chronic thyroid hormone deficency for the duration of the study. We chose not to include a chronic hyperthyroid treatment group because even the lowest dose of T4 tested (3 mg/L) caused dangerous hypoglycemia and fatality ( Fig. 1D ,E). To validate the efficacy of treatments, plasma T3 levels were measured at 28 days post-transplant (during the acute intervention) and were confirmed to be significantly lower in the acute hypothyroid mice and significantly higher in the acute hyperthyroid group compared to euthyroid controls ( Thyroid weight (normalized to body weight) was significantly increased in both the chronic and acute hypothyroid groups compared to euthyroid, although this was most pronounced in the chronic group ( Supplementary Fig. 2A ). Moreover, we observed severe thyroid follicular atrophy and absence of colloid in the thyroid gland of mice with chronic hypothyroidism (Supplementary Fig. 2B ).
Consistent with the first study ( Fig. 1 ), acute hypothyroidism resulted in a transient decrease in body weight, which quickly recovered once the mice were taken off the iodinedeficient diet at 30 days post-transplant (Fig. 2C ). The initial weight loss in the chronic hypothyroid group plateaued after ~80 days and body weight remained stable thereafter (Fig.   2C ). The reduction in body weight was associated with a significant decrease in fat pad weight (relative to body weight) in the chronic hypothyroid mice at 27 weeks post-transplant ( Supplementary Fig. 3 ). Chronic hypothyroidism also led to elevated fasting blood glucose levels whereas acute hypothyroid mice remained normoglycemic throughout the study (Fig.   2C ). Acute hyperthyroidism had no effect body weight, but caused a transient decrease in blood glucose levels during the T4 treatment period (Fig. 2D) , consistent with the previous cohort of mice (Fig. 1D ). From this point forward all data from the two euthyroid groups were pooled, as their body weight and blood glucose levels were not significantly different.
To assess the development of the hESC-derived grafts under conditions of thyroid dysregulation, human C-peptide and blood glucose levels were measured in response to various secretagogues following transplant. Chronic hypothyroid mice exhibited elevated blood glucose levels during an oral mixed-meal challenge at all ages examined ( weeks post-transplant, respectively (Fig. 3C,D) . There was no effect of acute hypothyroidism on glycemia during any metabolic challenge (Fig. 3A,C ,D,G).
Beginning at 8 weeks post-transplant and persisting throughout the study, the chronic hypothyroid mice had significantly decreased human C-peptide levels compared to euthyroid control mice, both under fasting conditions (data not shown) and at 40 minutes following the oral mixed-meal (Fig. 3B) . Additionally, mice with acute hypothyroidism had a transient decrease in meal-stimulated human C-peptide levels compared to euthyroid mice at 16 weeks post-transplant, which was recovered by 25 weeks (Fig. 3B) . At 22 weeks post-transplant chronic hypothyroid mice exhibited severely blunted human C-peptide secretion during an i.p.
glucose challenge (Fig. 3E) , and also displayed altered C-peptide secretion kinetics compared to euthyroid mice (Fig. 3F) . While peak human C-peptide levels were observed at 60 minutes post-glucose administration in the chronic hypothyroid mice (~2.5-times higher than basal), the other groups had reached similar peak C-peptide levels at 30 minutes and were approaching basal levels by 60 minutes (Fig. 3F) . The acute hyperthyroid group also had significantly reduced human C-peptide levels at 30 minutes following the glucose injection (Fig. 3E ), but unlike the chronic hypothyroid group they possessed similar human C-peptide secretion kinetics to euthyroid control mice (Fig. 3F) . Consistent with the meal and glucose challenges, the chronic hypothyroid group also displayed significantly reduced human insulin levels both at fasting and 15 minutes post-arginine injection compared to euthyroid mice at 24
Page 12 of 48 Diabetes weeks post-transplant (Fig. 3H) . Interestingly, these mice also had higher plasma glucagon levels post-arginine (Fig. 3I) , as well as elevated GLP-1 levels both at fasting and postarginine ( Fig. 3J ) compared to euthyroid mice.
Chronic hypothyroidism affects the endocrine composition of hESC-derived grafts, but not the endogenous pancreas
Theracyte™ devices were harvested at 27 weeks post-transplant for qPCR and histology analysis. Although the chronic hypothyroid group displayed decreased plasma human insulin, and increased plasma glucagon levels (Fig. 3H,I ), INS and GCG mRNA levels in these hESC-derived grafts were not significantly different from the euthyroid group (Fig. 4) .
However, chronic hypothyroidism resulted in significantly increased levels of SST, GHRL, and ISL1, as well as a pronounced reduction in IAPP and G6PC2 mRNA in hESC-derived grafts compared to grafts from euthyroid controls (Fig. 4) . Acute hyperthyroidism also caused a mild, but significant reduction in graft IAPP and G6PC2, and elevated GCG mRNA levels (Fig. 4) .
Given that the most pronounced effects on graft function and gene expresssion were a result of chronic hypothyroidism (Figs 3 and 4) , we focussed our detailed characterization of graft composition on the chronic hypothyroid versus euthyroid mice. Thyroid hormone deficiency did not impact the overall formation of endocrine (synaptophysin+) or ductal (CK19+) cells from hESCs (Fig. 5A ), but appeared to promote differentiation towards an α-cell lineage at the expense of β-cells (Fig. 5B,C) . Indeed, grafts from chronic hypothyroid mice contained a significantly lower fraction of insulin+ cells and more than twice as many glucagon+ cells compared to euthyroid grafts (Fig. 6A) . Thus there was a significantly higher Page 13 of 48 Diabetes ratio of glucagon:insulin immunoreactive cells in hESC-derived grafts from chronic hypothyroid compared to euthyroid mice, whereas the glucagon:insulin ratio in the endogenous pancreas was not affected by chronic hypothyroidism (Fig. 6B) . Moreover, thyroid hormone deficiency did not affect the β-cell area per islet in the endogenous pancreas (Fig. 6C) . At 27 weeks post-transplant proliferating (PCNA+) endocrine cells were rare and there were no obvious differences in the number of proliferating insulin+ or glucagon+ cells between treatment groups ( Supplementary Fig. 4 ). Despite the significant increase in SST transcript levels in chronic hypothyroid grafts (Fig. 4) , there was no significant difference in the fraction of somatostatin+ cells between groups (quantification not shown; Supplementary   Fig. 5 ). Pancreatic polypeptide (PP) immunoreactivity was rare in grafts and did not appear to differ between groups, although this was not quantified (Supplementary Fig. 5 ).
Interestingly, chronic hypothyroid grafts had an ~8-fold increase in GHRL transcript levels ( Fig. 4) and a significantly higher proportion of ghrelin+ cells (relative to DAPI+ cells;
Figs 5C and 6A) compared to euthyroid grafts. Moreover, while ghrelin+ cells were abundant in the hESC-derived engrafted tissue, they were only rarely detected in the endogenous pancreas (Fig. 6D) . Chronic hypothyroid grafts contained approximately equal proportions of ghrelin+ and insulin+ cells, whereas euthyroid grafts had ~4 insulin+ cells for every 1 ghrelin+ cell (Fig. 6E ). In the pancreas the ratio of ghrelin:insulin immunoreactive cells was not affected by exposure to chronic hypothyroidism (Fig. 6E ). There was no significant difference in circulating acylated (active) or unacylated (inactive) ghrelin levels between groups, but the ratio of unacylated:acylated ghrelin was ~2-times higher in the chronic hypothyroid mice compared to euthyroid mice (Fig. 6F ).
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Thyroid hormone deficiency affects β-cell maturation in hESC-derived grafts, but not the endogenous pancreas
Chronic hypothyroidism resulted in a reduced number of hESC-derived β-cells (Figs 5 and 6), which may explain the decreased absolute human C-peptide levels compared to euthyroid mice ( Figs 3B,E,H) . However, the disrupted human insulin secretion kinetics in chronic hypothyroid mice (Fig. 3D) , suggested that the maturation status of individual hESCderived β-cells may also be altered by thyroid hormone deficiency. Based on evidence that islet MAFA expression was regulated by thyroid hormones in neonatal rats (12), we examined expression of MAFA in grafts and the endogenous mouse pancreas. Although MAFA transcript levels were not affected in whole grafts (Fig. 4) , we observed substantial heterogeneity in nuclear MAFA immunoreactivity within the hESC-derived insulin+ population from chronic hypothyroid mice, but no difference in MAFA expression within the endogenous pancreas of hypothyroid versus euthyroid mice (Fig. 7A) .
Similarly, hypothyroidism also caused decreased NKX2.2 immunoreactivity in the grafts, but no differences were observed between groups in the endogenous pancreas (Fig. 7B ).
Additionally there was less amylin immunoreactivity within the insulin+ cell population in the hypothyroid compared to euthyroid grafts (Fig. 7C) , confirming the significant reduction in overall gene expression of IAPP in hypothyroid grafts (Fig. 4) ; amylin immunoreactivity was not affected in the β-cells from the endogenous pancreas (Fig. 7C ).
HESC-derived pancreatic progenitor cells were also treated in vitro with T3 during Stage 4 to determine if the effects on graft maturation in vivo might be a result of direct action by thyroid hormones. Consistent with our in vivo study, we observed reduced GHRL, GCG,
and ARX mRNA during Stage 5 following treatment with either 500 nM or 1000 nM T3 Fig. 6 ). T3 treatment also increased mRNA levels of INS and mature β-cell markers, G6PC2, IAPP, and MAFA during Stage 6 ( Supplementary Fig. 6 ).
Discussion
The high incidence of thyroid disease in patients with T1D (8) means that hESCderived pancreatic progenitor cells transplanted into these patients may be exposed to abnormal thyroid hormone levels in vivo. Notably, we found that chronic thyroid hormone deficiency had a detrimental impact on hESC-derived β-cell development and appeared to promote the differentiation of pancreatic progenitor cells towards α-and ε-cell lineages at the expense of β-cell formation. Beginning at 8 weeks post-transplant (and persisting throughout the study), grafts from chronic hypothyroid mice secreted less than half as much human Cpeptide than grafts from euthyroid mice. Blunted human C-peptide secretion was also observed in mice acutely exposed to hypothyroidism, but this effect was transient and fully recovered at 25 weeks post-transplant. Chronic hypothyroid mice also displayed impaired glucose-stimulated insulin secretion kinetics, suggesting that the maturation status of β-cells was affected by thyroid hormone deficiency. The elevated plasma glucagon and GLP-1 levels in chronic hypothyroid mice pointed to preferential formation of α-cells in hESC-derived grafts exposed to thyroid hormone deficiency. Indeed, grafts harvested from chronic hypothyroid mice contained approximately three-times fewer insulin+ cells and more than twice as many glucagon+ cells as grafts from euthyroid mice. It is unclear from these studies whether thyroid hormone deficiency altered the lineage commitment of differentiating endocrine cells, thus resulting in a fate-switch towards α-cells at the expense of β-cells, or if
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perhaps thyroid hormone is required for survival and/or expansion of newly differentiated β-cells. T3-treated neonatal rats had increased β-cell proliferation but no measureable change in beta cell apoptosis (12) . While proliferation of hESC-derived endocrine cells was not affected by thyroid hormone deficiency in our study after 27 weeks, it is possible that impaired β-cell replication and/or increased β-cell apoptosis may have occurred in hypothyroid grafts at an earlier time point.
Thyroid hormone deficiency resulted in heterogeneous protein expression of nuclear MAFA as well as reduced NKX2.2 and amylin levels, important markers of mature β-cells.
IAPP (amylin) and G6PC2 mRNA levels were also significantly reduced in grafts from hypothyroid mice compared to euthyroid controls, whereas the observed differences in insulin+, glucagon+, and MAFA+ cells were not reflected at the level of gene expression.
Since mRNA levels represent the whole population of hESC-derived cells (including all endocrine cell types, ductal cells etc.), examining protein expression in individual insulin+ cells by immunofluorescent staining is a more accurate assessment of the hESC-derived β-cell phenotype. The various lines of evidence pointing to a β-cell deficiency in hypothyroid mice is consistent with our previous observations in nude rats implanted with hESC-derived progenitor cells (16) . Interestingly, nude rats had significantly higher circulating T3 levels than SCID-beige mice, and also had improved glucose-stimulated human insulin secretion, a higher proportion of insulin:glucagon in grafts and more consistent nuclear MAFA expression in hESC-derived β-cells than SCID-beige mice (16) . Neonatal rats with hypothyroidism also exhibited decreased islet MAFA expression (12) , which is consistent with our findings and suggests a potential role for thyroid hormone in regulating β-cell maturation. This is further supported by evidence that thyroid hormones bind directly to the thyroid hormone response Ghrelin production by hESC-derived grafts also proved to be interesting in this study.
Grafts from euthyroid mice contained substantially higher (200X) ghrelin mRNA levels compared to human islets and a 4:1 ratio of insulin:ghrelin immunoreactive cells, whereas ghrelin+ cells were exceedingly rare (< 0.5%) in the adult human and mouse pancreas. This disprepancy was even further amplified in the chronic hypothyroid grafts, which contained ~1250X more ghrelin mRNA than human islets and approximately a 1:1 ratio of insulin:ghrelin immunoreactive cells. In human fetal pancreas ghrelin+ cells constitute a relatively high proportion (~10%) of endocrine cells (17) . Therefore the high ghrelin levels in chronic hypothyroid grafts could reflect graft immaturity or may simply indicate a shift in lineage commitment during development. Grafts from chronic hypothyroid mice also contained less NKX2.2 immunoreactivity, which was previously shown to be required for specification and maintenance of β-cell fate (18) . Moreover, the absence of NKX2.2 in mice resulted in a dramatic expansion of ghrelin-producing cells at the expense of β-cells (18) .
Interestingly, patients with hypothyroidism were reported to have elevated serum ghrelin levels (acylated and unacylated), which was normalized by thyroxine treatment (19) .
Although the chronic hypothyroid mice in our study did not produce elevated circulating ghrelin levels, there was clearly an effect of thyroid hormone deficiency to induce ghrelin locally within hESC-derived grafts. Pancreatic ghrelin serves as a local regulator of insulin release even though it may not contribute to the circulating ghrelin levels (20) . Therefore, ghrelin may be acting in a paracrine manner to impair insulin secretion in the hESC-derived grafts from chronic hypothyroid mice.
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Although thyroid hormone deficiency caused clear effects on the transplanted human pancreatic progenitor cells, the endogenous pancreas appeared to be largely unaffected in our study. It is possible that developing endocrine cells are more susceptible to thyroid hormone dysregulation than adult islet cells or that human pancreatic cells are more susceptible than mouse cells, although we suspect the former is more likely. It is also possible that the effects on differentiation of hESC-derived cells are due to the profoundly disrupted metabolic control in the mice with hyper-or hypothyroidism. However, we have previously observed efficient graft maturation and robust human C-peptide production in the setting of chronic hyperglycemia (4), and thus feel that the impaired glycemic control in hypothyroid mice is unlikely to be the underlying cause of impaired maturation in the current study. Thyroid hormones are also known to profoundly affect the stress response in vivo (12) , which could also indirectly mediate the observed effects of hypothyroidism on β-cell maturation.
Interestingly, dexamethasone treatment of neonatal rat islets blocked the T3-mediated induction of Mafa mRNA and glucose-stimulated insulin secretion ex vivo (12) . Our previous discovery that T3 treatment at late stages of hESC differentiation enhanced β-cell maturation in culture (13) Clinically, hyperthyroidism can lead to elevated blood glucose levels, possibly due to enhanced gluconeogenesis and increased absorption of sugars from the intestine (21), whereas the opposite typically occurs with hypothyroidism. Interestingly, we observed contradictory effects of thyroid hormones on blood glucose homeostasis in SCID-beige mice.
Hyperthyroidism led to hypoglycemia whereas hypothyroidism caused hyperglycemia compared to euthyroid controls. Hypothyroidism also caused decreased body weight in mice whereas in humans hypothyroidism generally leads to weight gain. Although our data differs from the clinical situation, these findings are consistent with previous studies examining hyperthyroidism and hypothyroidism in rodents. For example, rodents that received subcutaneous T3 injections had lowered fasting glucose levels compared to controls (12, 22) , and hypothyroidism in rats (induced via thyroidectomy and PTU or methimazole treatment) caused decreased body weight (12, 23) and increased serum glucose levels (23). The differences between human and rodent thyroid physiology that account for these opposing phenotypes are currently unknown.
Stem cell-derived pancreatic progenitor cells are currently being transplanted into patients with T1D in a phase 1/2 clinical trial with Viacyte. Our findings raise the possibility that the maturation and ultimate function of the transplanted cells can be influenced by the hormononal and metabolic milieu of the cells. Specifically, we recommend that eligible patients are screened for thyroid dysfunction and treated accordingly to reduce the risk of offtarget cell differentiation leading to compromised graft function. Alternatively, hESCs could be differentiated to a more mature stage of development in vitro as we have recently described Page 20 of 48 Diabetes (13) , to minimize the maturation period following transplantation. It is possible that more mature hESC-derived cells will be less susceptible to altered levels of thyroid hormones because they are closer to adult cells, although this remains to be examined. 
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